Literature DB >> 16083934

Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene.

Lydia Aldaz-Carroll1, J Charles Whitbeck, Manuel Ponce de Leon, Huan Lou, Lewis K Pannell, Jacob Lebowitz, Christiana Fogg, Christine L White, Bernard Moss, Gary H Cohen, Roselyn J Eisenberg.   

Abstract

We reported that immunization with recombinant proteins derived from vaccinia virus (VV) particles could provide protection against infection. Here we describe the physical and antigenic properties of the L1R membrane protein. The recombinant protein (L1R(185t)) was secreted as a monomer and correct folding was suggested by the presence of three intramolecular disulfide bonds and binding to conformation-specific monoclonal antibodies (MAbs). Furthermore, anti-L1R(185t) rabbit antisera exhibited potent virus-neutralizing activity against the IMV form of VV. We raised six MAbs against L1R(185t). Three recognized linear epitopes (residues 118--128) and neutralized IMV infectivity. These MAbs blocked binding of each other to L1R(185t) but failed to block binding of two previously described neutralizing anti-L1R MAbs, 7D11 and 2D5. The latter two antibodies blocked each other in binding L1R(185t). Thus, two antigenic sites on L1R overlap functional domains and based on recent structural studies these are found in accessible regions of the IMV L1R protein.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16083934     DOI: 10.1016/j.virol.2005.07.006

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  36 in total

1.  Vaccinia virus F9 virion membrane protein is required for entry but not virus assembly, in contrast to the related L1 protein.

Authors:  Erica Brown; Tatiana G Senkevich; Bernard Moss
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  Characterization of a vaccinia virus mutant with a deletion of the D10R gene encoding a putative negative regulator of gene expression.

Authors:  Susan Parrish; Bernard Moss
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus.

Authors:  Zhaochun Chen; Patricia Earl; Jeffrey Americo; Inger Damon; Scott K Smith; Yi-Hua Zhou; Fujuan Yu; Andrew Sebrell; Suzanne Emerson; Gary Cohen; Roselyn J Eisenberg; Juraj Svitel; Peter Schuck; William Satterfield; Bernard Moss; Robert Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-25       Impact factor: 11.205

4.  A conserved poxvirus NlpC/P60 superfamily protein contributes to vaccinia virus virulence in mice but not to replication in cell culture.

Authors:  Tatiana G Senkevich; Linda S Wyatt; Andrea S Weisberg; Eugene V Koonin; Bernard Moss
Journal:  Virology       Date:  2008-02-20       Impact factor: 3.616

5.  Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein.

Authors:  Hua-Poo Su; Joseph W Golden; Apostolos G Gittis; Jay W Hooper; David N Garboczi
Journal:  Virology       Date:  2007-08-03       Impact factor: 3.616

6.  Antibody responses to vaccinia membrane proteins after smallpox vaccination.

Authors:  Steven J Lawrence; Kathleen R Lottenbach; Frances K Newman; R Mark L Buller; Clifford J Bellone; John J Chen; Gary H Cohen; Roselyn J Eisenberg; Robert B Belshe; Samuel L Stanley; Sharon E Frey
Journal:  J Infect Dis       Date:  2007-06-04       Impact factor: 5.226

7.  Characterization of murine antibody responses to vaccinia virus envelope protein A14 reveals an immunodominant antigen lacking of effective neutralization targets.

Authors:  Xiangzhi Meng; Thomas Kaever; Bo Yan; Paula Traktman; Dirk M Zajonc; Bjoern Peters; Shane Crotty; Yan Xiang
Journal:  Virology       Date:  2018-03-17       Impact factor: 3.616

8.  Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.

Authors:  Cassandra L Braxton; Shelby H Puckett; Steven B Mizel; Douglas S Lyles
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

9.  Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge.

Authors:  Yuhong Xiao; Yuhong Zeng; Edward Alexander; Shyam Mehta; Sangeeta B Joshi; George W Buchman; David B Volkin; C Russell Middaugh; Stuart N Isaacs
Journal:  Vaccine       Date:  2012-11-12       Impact factor: 3.641

10.  Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization.

Authors:  Kaori Shinoda; Linda S Wyatt; Kari R Irvine; Bernard Moss
Journal:  Virol J       Date:  2009-03-03       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.